fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Aluminum hydroxide & magnesium hydroxide

All products: not a benefit

Maalox TC · DIN 02162369 · 120 mg & 60 mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-08-07 — choose a marketed DIN from the same-category list.Discontinued August 7, 2002 · checked November 18, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-08-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-08-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Maalox TC · DIN 02162369 Manufacturer: Novartis Pharma Canada Inc.; listing date 1998-03-17 Health Canada: Cancelled post market since 2002-08-07 · brand MAALOX TC SUSPENSION · ATC A02AD01 ORDINARY SALT COMBINATIONS · form Suspension · route Oral · ingredients MAGNESIUM HYDROXIDE 300 MG/5ML, ALUMINUM HYDROXIDE 600 MG/5ML · company Novartis consumer health canada inc. · schedule Non-prescription drugs
Re-check Health Canada status and shortages (live) · Health Canada product record

Maalox TC: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162369)

Source record
DIN 02162369: Maalox TC Raw flags: notABenefit=Y, sec3=Y Item: 560400016; group id 645; item number 1623; lccId None; manufacturer id NOV Source form: O/L; strength: 120mg & 60mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162369 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20087
Interchangeable products
Diovol EX · DIN 00491217 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since August 7, 2002 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:04 Antacids and Adsorbents) and how they are covered
No products matched this class search: “56:04”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Maalox TC: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026